TATVA

What Tatva Chintan Pharma Chem promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 25 tracked 4 delivered 6 missed 15 open
  • FY26 Revenue Growth delivered, diluted said Q1 FY26 Promised: upward of 25% Q1 FY27: Promise relates to a completed fiscal year. No new updates.
  • SDA Volume Growth went quiet said Q1 FY26 Promised: 40% to 70% Q1 FY27: Promise relates to a completed fiscal year. No new updates.
  • Semiconductor Commercialization delayed said Q1 FY26 Promised: slow commercialization to begin in 2027, full-scale by 2029 Q1 FY27: we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 25 tracked commitments for Tatva Chintan Pharma Chem — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens